FDA’s advisory committee has endorsed Truqap plus abiraterone and ADT as a treatment option with a favorable benefit-risk ...
- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results